IL-18 AND ADROPIN LEVELS IN PATIENTS WITH ACUTE ISCHEMIC STROKE

Abstract

Objective Atherosclerosis, one of the prominent factors causing dysfunctional vascular events in stroke patients, is a multi-factorial and complex process in which endothelial dysfunction and vascular inflammation play significant roles. This study aimed to investigate the relationships between serum levels of IL-18 and adropin, associated with endothelial dysfunction and inflammatory processes in acute ischemic stroke patients, with epidemiological, clinical, radiological findings and stroke severity. Materials and Methods Sixty-one patients diagnosed with acute ischemic stroke and 30 healthy individuals were included in the study as the patient and control groups. In the patient group, the stroke sub-groups and severity were determined etiologically and clinically. Venous blood samples were obtained within the first 24 hours in the patient group, and at any time in the control group, their serums were separated and stored at -80°C. IL-8 and adropin levels were determined using the ELISA method. The relationships between patient and control groups’ IL-18 and adropin levels and ischemic stroke were analyzed statistically. Results The adropin level was statistically significantly lower in the patient group than the control group (398.01±403.51 and 509.42±1492.89, respectively; p=0.041). The IL-18 levels of the study and control groups were similar (24.87±14.26 and 21.11±14.93, respectively; p=0.112). There was no relationship between the IL-18 and adropin levels determined with stroke risk factors, stroke sub-groups, and stroke severity. Conclusion These results showed that low adropin levels could be used to indicate atherosclerosis in the risk prediction scales of ischemic stroke. The absence of a difference between the patient group with acute ischemic stroke and the control group regarding the first 24-hour mean serum IL-18 level suggested that IL-18 could play a role as a late-stage cytokine in ischemia-related inflammation.

Keywords

• ischemic stroke
• adropin
• IL-18
• inflammation
• endothelial dysfunction

AKUT İSKEMİK İNMELİ HASTALARDA IL-18 VE ADROPİN DÜZEYLERİ

Abstract

Amaç İnmeli hastalarda disfonksiyonel vasküler olaylara yol açan önde gelen faktörlerden bir tanesi olan ateroskleroz; endotelyal disfonksiyon ve vasküler inflamasyonun önemli bir rol oynadığı çok faktörlü ve kompleks bir süreçtir. Biz bu çalışmada endotel disfonksiyonu ve inflamatuar süreçlerle ilişkisi gösterilmiş olan IL- 18 ve adropininin akut iskemik inme hastalarındaki serum düzeyleri ile epidemiyolojik, klinik, radyolojik bulgular ve inme şiddeti arasındaki ilişkiyi araştırmayı amaçladık. Gereç ve Yöntem Çalışmamıza akut iskemik inme tanısı konulan 61 hasta ve kontrol grubu olarak 30 sağlıklı birey alındı. Hasta grubunda etiyolojik ve klinik olarak inme alt grupları ve inme şiddeti belirlendi. Hasta grubundan ilk 24 saatte, kontrol grubundan herhangi bir zamanda venöz kan örnekleri alınarak serumları ayrıldı ve -80⁰C’de saklandı. ELISA yöntemi kullanılarak IL-8 ve adropin düzeyleri belirlendi. Hasta ve kontrol gruplarının IL-18 ve adropin düzeyleri ile iskemik inme arasındaki ilişkiler istatistiksel olarak analiz edildi. Bulgular Adropin düzeyi hasta grubunda kontrol grubuna göre istatistiksel olarak anlamlı derecede düşüktü (sırasıyla 398.01±403.51 ve 509.42±1492.89; p=0.041). Çalışma ve kontrol gruplarının IL-18 düzeyleri benzerdi (sırasıyla 24.87±14.26 ve 21.11±14.93; p=0.112). İnme risk faktörleri, inme alt grupları ve inme şiddeti ile belirlenen IL-18 ve adropin düzeyleri arasında ilişki yoktu. Sonuç Bu bulgular, düşük adropin düzeylerinin ateroskleroz göstergesi olarak iskemik inme risk tahmini ölçeklerinde kullanılabileceğini göstermiştir. Akut iskemik inmeli hasta grubu ile kontrol grubu arasında ortalama serum IL-18 düzeyi açısından fark olmaması, IL-18'in iskemiye bağlı inflamasyonda geç dönem bir sitokin olarak rol oynayabileceğini düşündürmüştür.

Keywords

• iskemik inme
• adropin
• IL-18
• inflamasyon
• endotel disfonksiyonu

References

1. 1. Monica, W. H. O. & Project Principal Investigators. The World Health Organization MONICA project (monitoring trends and determinants in cardiovascular disease): a major international collabaration. Journal of clinical epidemiology. Oxford; New York: Pergamon Press 1988; vol. 41, no. 2.
2. 2. Ihle-Hansen H, Thommessen B, Wyller TB, Engedal K, Fure B. Risk factors for and incidence of subtypes of ischemic stroke. Functional neurology 2012; 27: 1-35.
3. 3. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003; 4(5): 399-415.
4. 4. Basic Kes V, Simundic AM, Nikolac N, et al. Pro- inflammatory and anti-inflammatory cytokines in acute ischemic stroke and their relation to early neurological deficit and stroke outcome. Clin Biochem. 2008; 41(16-17): 1330-4.
5. 5. Dinarello CA. Novel targets for interleukin 18 binding protein. Ann Rheum Dis. 2001; 60[Suppl 3]:18–24.
6. 6. Gürkaş E, Orhan G, Ak F. The relationship of IL-18 levels with early and late clinical findings and infarct volume in patients with acute ischemic stroke. Turkish Journal of Cerebrovascular Diseases 2012; 18(1): 10-15.
7. 7. Mallat Z, Corbaz A, Scoazec A, et al. Expression of interleukin- 18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104: 1598 –1603.
8. 8. Blankenberg S, Luc G, Ducimetiere P, et al. Interleukin-18 and risk of coronary heart disease in European men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003; 108: 2453– 2459.

9. 9. Stott DJ, Welsh P, Rumley A, et al. Adipocytokines and risk of stroke in older people: a nested case-control study. Int J Epidemiol. 2009; 38:253–61.
10. 10. Zaremba J, Losy J. Interleukin-18 in acute ischaemic stroke patients. Neurol Sci. 2003; 24:117–24.
11. 11. Sarchielli P, Nardi K, Chiasserini D, et al. Immunological profile of silent brain infarction and lacunar stroke. PLoS One. 2013; 8(7):e68428.
12. 12. Bossù P, Salani F, Cacciari C, et al. Disease outcome, alexithymia and depression are differently associated with serum IL-18 levels in acute stroke. Curr Neurovasc Res. 2009; 6:163–70.
13. 13. Yu XH, Qian K, Jiang N, et al. ABCG5/ABCG8 in cholesterol excretion and atherosclerosis. Clin. Chim. Acta 2014; 428: 82–88.
14. 14. Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8:468–81.
15. 15. Shahjouei S, Ansari S, Pourmotabbed T, Zand R. Potential roles of adropin in central nervous system: review of current literature. Front. Mol. Biosci. 2016; 3: 25.
16. 16. Lovren F, Pan Y, Quan A, et al. Adropin is a novel regulator of endothelial function. Circulation 2010; 122 (11 Suppl. 1): 185- 192.
17. 17. Kathir K, Adams MR. Endothelial dysfunction as a predictor of acute coronary syndromes. Semin Vasc Med. 2003;3:355–62.
18. 18. Wu L, Fang J, Chen L, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med. 2014;52:751–8.
19. 19. Topuz M, Celik A, Aslantas T, at al. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J. Investig. Med. 2013; 61 (8): 1161–1164.
20. 20. Esper RJ, Nordoby RA, Vilarino JO, et al. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 2006; 5: 4.
21. 21. Zhang C, Zhao L, Xu W, et al. Correlation of serum adropin level with coronary artery disease. Zhonghua Yi Xue Za Zhi 94 2014; 94(16): 1255–1257.
22. 22. Yu HY, Zhao P, Wu MC, et al. Serum adropin levels are decreased in patients with acute myocardial infarction. Regul. Pept. 2014; 190–191: 46–49.
23. 23. Gunaydin M, Aygun A, Usta M, at al. Serum adropin levels in patients with acute ischemic stroke. Medicine 2019; 8(3): 698- 702.
24. 24. Yang C, DeMars KM, Candelario-Jalil E. Abstract TP277: Adropin is Profoundly Neuroprotective in Experimental Ischemic Stroke. Stroke 2017; 48(suppl_1), ATP277-ATP277.
25. 25. Yang C, Sanz BD, DeMars KM, at al. Abstract WP315: Neuroprotective Effects of Endogenous Adropin in Experimental Ischemic Stroke. Stroke 2020; 51(Suppl_1), AWP315- AWP315.
26. 26. Georgakis MK, Gill D, Rannikmäe K, at al. Genetically Determined Levels of Circulating Cytokines and Risk of Stroke. Circulation. 2019; 139:256–68.
27. 27. Yuen CM, Chiu CA, Chang LT, et al. Level and value of interleukin- 18 after acute ischemic stroke. Circ J. 2007; 71(11): 1691-6.
28. 28. Ormstad H, Aass HCD, Lund-Sørensen N, at al. Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume. Journal of neurology 2011; 258(4): 677-685.
29. 29. Hao Y, Ding J, Hong R, at al. Increased interleukin-18 level contributes to the development and severity of ischemic stroke. Aging (Albany NY) 2019; 11(18): 7457.
30. 30. Jander S, Schroeter M, Stoll G. Interleukin-18 expression after focal ischemia of the rat brain: association with the late-stage inflammatory response. J Cereb Blood Flow Metab 2002; 22: 62–70.
31. 31. Wheeler RD, Boutin H, Touzani O, et al. No Role for Interleukin- 18 in Acute Murine Stroke-Induced Brain Injury. J Cereb Blood Flow Metab 2003; 23(5): 531-5.